Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 8Lymphoma 7Lymphoma, Non-Hodgkin 6Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Follicular 5Recurrence 3Neoplasms 2Leukemia, B-Cell 2Burkitt Lymphoma 2Neoplasm, Residual 1Mature B-Cell Malignancies 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lymphatic Diseases 1Leukemia, Hairy Cell 1Heart Failure 1Dendritic Cell Sarcoma, Interdigitating 1Cytokine Release Syndrome 1

Interventions

fludarabine 3Cyclophosphamide 3obinutuzumab 2acalabrutinib 2ricolinostat 1pirtobrutinib 1idelalisib 1ibrutinib 1fludarabine phosphate 1Rituximab 1Mesna 1Leukapheresis 1ARQ531 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leukemia, B-Cell × obinutuzumab × 30 days × Clear all
NCT07624799 2026-06-03

PACIFIC

French Innovative Leukemia Organisation

Phase 2 Not yet recruiting
82 enrolled
LymphoidOther hematologic neoplasm

Leukemia, B-Cell

NCT06651970 2026-05-18

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

AstraZeneca

Phase 4 Recruiting
60 enrolled
LymphoidOther hematologic neoplasm

Heart Failure, Lymphatic Diseases, Leukemia, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡